Altimmune (ALT) to Release Earnings on Thursday

Altimmune (NASDAQ:ALT) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $6.11 on Tuesday. Altimmune has a 52-week low of $5.28 and a 52-week high of $14.84. The company’s 50 day moving average price is $7.00 and its 200-day moving average price is $7.20.

Analyst Ratings Changes

ALT has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price on the stock. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Wednesday, February 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.